Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich PS, Milpied N, Turlure P, Nguyen S, Sirvent A, Bulabois CE, Berceanu A, Charbonnier A, Chevallier P, Bay JO, Neven B, Jubert C, Mohty M, Rubio MT, Peffault de Latour R.

Biol Blood Marrow Transplant. 2019 May 24. pii: S1083-8791(19)30324-6. doi: 10.1016/j.bbmt.2019.05.013. [Epub ahead of print]

PMID:
31129355
2.

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation.

Charles J, Giovannini D, Terzi N, Schwebel C, Sturm N, Masson D, Leccia MT, Cahn JY, Manches O, Bulabois CE, Chaperot L.

Exp Hematol Oncol. 2019 Mar 28;8:8. doi: 10.1186/s40164-019-0132-2. eCollection 2019.

3.

De novo adult acute myeloid leukemia patients display at diagnosis functional deregulation of redox balance correlated with molecular subtypes and overall survival.

Mondet J, Lo Presti C, Garrel C, Skaare K, Mariette C, Carras S, Park S, Carré M, Bulabois CE, Molina L, Gressin R, Thiebaut A, Courby S, Socoro-Yuste N, Faure P, Mc Leer-Florin A, Cahn JY, Mossuz P.

Haematologica. 2019 Feb 28. pii: haematol.2018.206821. doi: 10.3324/haematol.2018.206821. [Epub ahead of print]

4.

Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).

Fayard A, Daguenet E, Blaise D, Chevallier P, Labussière H, Berceanu A, Yakoub-Agha I, Socié G, Charbonnier A, Suarez F, Huynh A, Mercier M, Bulabois CE, Lioure B, Chantepie S, Beguin Y, Bourhis JH, Malfuson JV, Clément L, Peffault de la Tour R, Cornillon J.

Bone Marrow Transplant. 2019 Feb 15. doi: 10.1038/s41409-019-0475-7. [Epub ahead of print]

PMID:
30770870
5.

HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation.

Ducreux S, Dubois V, Amokrane K, Yakoub-Agha I, Labalette M, Michallet M, Rubio MT, Kennel A, Forcade E, Lafarge X, Bulabois CE, Masson D, Daguindau E, Devys A, Moalic V, Quelvennec E, Boudifa A, Picard C, Van Endert P, de Matteis M, Delbos F, Filloux M, Pedron B, Renac V, Hau F, Bonneau J, Parissiadis A, Fort M, Dormoy A, Maillard N, Jollet I, Chevallier P, Cesbron A, Bay JO, Quainon F, Garnier F, Socié G, Loiseau P, Porcher R, Peffault de Latour R; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25133. [Epub ahead of print]

6.

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.

Augeul-Meunier K, Chretien ML, Stoppa AM, Karlin L, Benboubker L, Diaz JMT, Mohty M, Yakoub-Agha I, Bay JO, Perrot A, Bulabois CE, Huynh A, Mercier M, Frenzel L, Avet-Loiseau H, de Latour RP, Cornillon J.

Bone Marrow Transplant. 2018 Jun;53(6):749-755. doi: 10.1038/s41409-018-0122-8. Epub 2018 Mar 9.

PMID:
29523884
7.

Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, Le Niger C, Robin C, Ladaique P, Lapusan S, Deconinck E, Rolland C, Foote AM, François A, Jacquot C, Tardivel R, Tiberghien P, Bosson JL; Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group.

JAMA Oncol. 2018 Apr 1;4(4):468-475. doi: 10.1001/jamaoncol.2017.5123.

8.

[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau É, Dumesnil C, Guillaume T, Huynh A, Levrat SM, Menard AL, Michallet M, Pautas C, Poiré X, Ravinet A, Yakoub-Agha I, Bazarbachi A.

Bull Cancer. 2017 Dec;104(12S):S84-S98. doi: 10.1016/j.bulcan.2017.05.009. Epub 2017 Nov 26. Review. French.

PMID:
29179894
9.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

PMID:
28911060
10.

How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome.

Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau E, Dumesnil C, Guillaume T, Huynh A, Masouridi Levrat S, Menard AL, Pautas C, Poiré X, Ravinet A, Michallet M, Bazarbachi A.

Curr Res Transl Med. 2017 Apr - Jun;65(2):65-69. doi: 10.1016/j.retram.2017.06.001. Epub 2017 Jul 4. Review.

PMID:
28687223
11.

Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord.

Nguyen S, Achour A, Souchet L, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Francois S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Lejeune J, Béziat V, Rocha V, Rio B, Chevret S, Vieillard V.

Bone Marrow Transplant. 2017 Oct;52(10):1428-1435. doi: 10.1038/bmt.2017.122. Epub 2017 Jun 26.

PMID:
28650455
12.

Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study.

Michallet M, Sobh M, Garban F, Bulabois CE, Yakoub-Agha I, Coiteux V, Dulery R, Rohrlich PS, Legrand F, Clement L, Praire A, Detrait M, Barraco F, Nicolini FE, Hequet O.

Leuk Lymphoma. 2018 Feb;59(2):372-380. doi: 10.1080/10428194.2017.1334120. Epub 2017 Jun 7.

PMID:
28587506
13.

Remission of a long-lasting sarcoidosis after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

Ginoux E, Kottler D, Anglaret B, Balme B, Bulabois CE, Skowron F.

JAAD Case Rep. 2016 Oct 12;2(5):408-410. eCollection 2016 Sep. No abstract available.

14.

Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.

Chevallier P, Labopin M, de La Tour RP, Lioure B, Bulabois CE, Huynh A, Blaise D, Turlure P, Daguindau E, Maillard N, Yakoub-Agha I, Guillerm G, Delage J, Contentin N, Bay JO, Beckerich F, Bourhis JH, Detrait M, Vigouroux S, François S, Legrand F, Guillaume T, Mohty M; SFGM-TC.

Cancer Med. 2016 Nov;5(11):3068-3076. doi: 10.1002/cam4.880. Epub 2016 Oct 17.

15.

Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.

Raberahona M, Wackenheim C, Germi R, Carré M, Bulabois CE, Thiébaut A, Lupo J, Semenova T, Cahn JY, Morand P, Epaulard O.

Transpl Infect Dis. 2016 Dec;18(6):889-895. doi: 10.1111/tid.12618. Epub 2016 Nov 24.

PMID:
27696681
16.

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S.

Bone Marrow Transplant. 2016 Mar;51(3):358-64. doi: 10.1038/bmt.2015.280. Epub 2015 Nov 23.

17.

Quantification of Howell-Jolly body-like inclusions in ganciclovir toxicity using CellaVision DM96 analyser.

Revol B, Thiebaut-Bertrand A, Carré M, Bulabois CE, Mossuz P, Mondet J.

Br J Haematol. 2016 Aug;174(4):637-9. doi: 10.1111/bjh.13784. Epub 2015 Oct 12. No abstract available.

PMID:
26456312
18.

Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D, Michallet M, Chevalier P, Raus N, El-Cheikh J, Tabrizi R, Huyn A, Buzyn A, Socié G, Vincent L, Guilhot F, Yakoub-Agha I, Lenain P, François S, Beckerich F, Lioure B, Bulabois CE, Deconinck E; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Biol Blood Marrow Transplant. 2015 Aug;21(8):1452-9. doi: 10.1016/j.bbmt.2015.04.020. Epub 2015 Apr 22.

19.

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Rubio MT, Labopin M, Blaise D, Socié G, Contreras RR, Chevallier P, Sanz MA, Vigouroux S, Huynh A, Shimoni A, Bulabois CE, Caminos N, López-Corral L, Nagler A, Mohty M.

Haematologica. 2015 May;100(5):683-9. doi: 10.3324/haematol.2014.119339. Epub 2015 Mar 13.

20.

Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.

Mondet J, Park JH, Menard A, Marzac C, Carillo S, Pourcelot E, Girodon F, Cabagnols X, Lodé L, Socoro N, Chauvet M, Bulabois CE, Cony-Makhoul P, Corm S, Cahn JY, Mossuz P.

Haematologica. 2015 May;100(5):e176-8. doi: 10.3324/haematol.2014.118927. Epub 2015 Feb 6. No abstract available.

21.

Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.

Gautier-Veyret E, Fonrose X, Tonini J, Thiebaut-Bertrand A, Bartoli M, Quesada JL, Bulabois CE, Cahn JY, Stanke-Labesque F.

Antimicrob Agents Chemother. 2015 Apr;59(4):2305-14. doi: 10.1128/AAC.04838-14. Epub 2015 Feb 2.

22.

Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

Rio B, Chevret S, Vigouroux S, Chevallier P, Fürst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Françoise S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Gluckman E, Ruggeri A, Buzyn A, Nguyen S, Simon T, Milpied N, Rocha V; Société Française de Greffe de Moelle et de Thérapie Cellulaire and Eurocord.

Biol Blood Marrow Transplant. 2015 Mar;21(3):445-53. doi: 10.1016/j.bbmt.2014.11.009. Epub 2014 Nov 18.

23.

Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

Chevallier P, Labopin M, Socie G, Rubio MT, Blaise D, Vigouroux S, Huynh A, Michallet M, Bay JO, Maury S, Yakoub-Agha I, Fegueux N, Deconinck E, Contentin N, Maillard N, Bulabois CE, Francois S, Oumedaly R, Raus N, Mohty M.

Eur J Haematol. 2015 May;94(5):449-55. doi: 10.1111/ejh.12451. Epub 2014 Oct 13.

PMID:
25238651
24.

[Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (Part 1)].

Blaise D, Nguyen S, Bay JO, Chevallier P, Contentin N, Dhédin N, Duléry R, Eliaou JF, Rubio MT, Suarez F, Bulabois CE, Cornillon J, Huynh A, Magro L, Michallet M, Paillard C, Turlure P, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):180-4. doi: 10.1016/j.patbio.2014.05.004. Epub 2014 Jun 25. French.

PMID:
24973859
25.

[Impact of anti-HLA antibodies on outcomes of allogeneic stem cell transplantation: a report by the SFGM-TC].

Loiseau P, Dubois V, Bonafoux B, Bulabois CE, Coiteux V, Eliaou JF, Labaky M, Michallet M, Renac V, Delbos F, Kennel A, Detrait M, Devys A, Galambrun C, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):226-9. doi: 10.1016/j.patbio.2014.05.007. Epub 2014 Jun 25. French.

PMID:
24973858
26.

[Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (part 2)].

Nguyen S, Blaise D, Bay JO, Chevallier P, Contentin N, Dhédin N, Duléry R, Eliaou JF, Rubio MT, Suarez F, Bulabois CE, Cornillon J, Huynh A, Magro L, Michallet M, Paillard C, Turlure P, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):185-9. doi: 10.1016/j.patbio.2014.05.002. Epub 2014 Jun 18. French.

PMID:
24954121
27.

Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.

Meunier M, Bulabois CE, Thiebaut-Bertrand A, Itzykson R, Carre M, Carras S, Garban F, Cahn JY.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1451-4. doi: 10.1016/j.bbmt.2014.05.031. Epub 2014 Jun 6.

28.

Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.

Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2014 May;20(5):646-54. doi: 10.1016/j.bbmt.2014.01.016. Epub 2014 Jan 22.

29.

Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Chevallier P, Labopin M, Milpied N, Bilger K, Socié G, Yakoub-Agha I, Michallet M, Bulabois CE, Maury S, Beguin Y, Bay JO, Blaise D, Maillard N, Guillerm G, Daguindeau E, Raus N, Mohty M.

Bone Marrow Transplant. 2014 Mar;49(3):361-5. doi: 10.1038/bmt.2013.186. Epub 2013 Dec 2.

PMID:
24292522
30.

[Diagnosis and treatment of CMV and EBV Reactivation as well as Post-transplant Lymphoproliferative Disorders following Allogeneic Stem Cell Transplantation: An SFGM-TC report].

Bay JO, Peffault de Latour R, Bruno B, Coiteux V, Guillaume T, Hicheri Y, Paillard C, Suarez F, Turlure P, Alain S, Bulabois CE, Socié G, Bauters F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):152-4. doi: 10.1016/j.patbio.2013.07.003. Epub 2013 Sep 4. French.

PMID:
24011961
31.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H; French AML Intergroup.

Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15.

32.

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.

Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I.

J Clin Oncol. 2012 Dec 20;30(36):4533-40. doi: 10.1200/JCO.2012.44.3499. Epub 2012 Oct 29.

33.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.

Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P; GOELAMS.

Am J Hematol. 2012 Dec;87(12):1052-6. doi: 10.1002/ajh.23311. Epub 2012 Aug 22.

34.

Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.

Tonini J, Thiébaut A, Jourdil JF, Berruyer AS, Bulabois CE, Cahn JY, Stanke-Labesque F.

Antimicrob Agents Chemother. 2012 Oct;56(10):5247-52. doi: 10.1128/AAC.00815-12. Epub 2012 Jul 30.

35.

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.

Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois CE, Tournilhac O, Buzyn A, Rio B, Moles MP, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau JL, Moreau P, Leux C, Mohty M.

Ann Oncol. 2012 Oct;23(10):2695-703. Epub 2012 Mar 22.

PMID:
22440229
36.

Unusual increased beta-globulins in an elderly patient.

Busser B, Millet S, Bulabois CE, Faure P, Renversez JC.

Clin Chem. 2011 Jul;57(7):948-51. doi: 10.1373/clinchem.2010.150425. No abstract available.

37.

Therapeutic impact and diagnostic performance of multiplex PCR in patients with malignancies and suspected sepsis.

Maubon D, Hamidfar-Roy R, Courby S, Vesin A, Maurin M, Pavese P, Ravanel N, Bulabois CE, Brion JP, Pelloux H, Timsit JF.

J Infect. 2010 Oct;61(4):335-42. doi: 10.1016/j.jinf.2010.07.004. Epub 2010 Jul 15.

PMID:
20637801
38.

Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial.

Chevallier P, Fornecker L, Lioure B, Béné MC, Pigneux A, Recher C, Witz B, Fegueux N, Bulabois CE, Daliphard S, Bouscary D, Vey N, Delain M, Bay JO, Turlure P, Bernard M, Himberlin C, Luquet I, Ifrah N, Harousseau JL; GOELAMS.

Leukemia. 2010 Jul;24(7):1380-5. doi: 10.1038/leu.2010.111. Epub 2010 May 27. No abstract available.

PMID:
20508614
39.

Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V, Tabrizi R, Bulabois CE, Cacheux V, Kuentz M, Dreyfus B, Dreger P, Rio B, Moles-Moreau MP, Bilger K, Bay JO, Leblond V, Blaise D, Tournilhac O, Dhédin N.

Haematologica. 2010 Jun;95(6):950-5. doi: 10.3324/haematol.2009.017814. Epub 2010 Jan 15.

40.

Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I, Mohty M, Robin M, Tabrizi R, Clement L, Bilger K, Larosa F, Contentin N, Huyn A, François S, Bulabois CE, Ceballos P, Bourrhis JH, Buzyn A, Cornillon J, Guillerm G, de Revel T, Bay JO, Guilhot F, Milpied N.

Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85. doi: 10.1016/j.bbmt.2009.09.002. Epub 2009 Sep 8.

41.

Mobile air-decontamination unit and filamentous fungal load in the hematology ward: how efficient at the low-activity mode?

Brenier-Pinchart MP, Coussa-Rivière L, Lebeau B, Mallaret MR, Bulabois CE, Ducki S, Cahn JY, Grillot R, Pelloux H.

Am J Infect Control. 2009 Oct;37(8):680-2. doi: 10.1016/j.ajic.2008.12.006. Epub 2009 Apr 10.

PMID:
19362390
42.

Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques.

Fricker-Hidalgo H, Bulabois CE, Brenier-Pinchart MP, Hamidfar R, Garban F, Brion JP, Timsit JF, Cahn JY, Pelloux H.

Clin Infect Dis. 2009 Jan 15;48(2):e9-e15. doi: 10.1086/595709.

PMID:
19072243
43.

Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.

Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, Lafon I, Cornillon J, Maakaroun A, Tizon A, Padrazzi B, Ifrah N, Gruel Y; GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang).

Haematologica. 2008 Oct;93(10):1488-94. doi: 10.3324/haematol.12948. Epub 2008 Aug 25.

44.

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, Moles MP, Bouabdallah K, Bulabois CE, Dupuis J, Rio B, Gratecos N, Yakoub-Agha I, Attal M, Tournilhac O, Decaudin D, Bourhis JH, Blaise D, Volteau C, Michallet M; Société Française de Greffe de Moëlle et de Thérapie Cellulaire.

J Clin Oncol. 2008 May 10;26(14):2264-71. doi: 10.1200/JCO.2007.14.1366. Epub 2008 Apr 7.

PMID:
18390969
45.

Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials.

Tavernier E, Le QH, de Botton S, Dhédin N, Bulabois CE, Reman O, Vey N, Lhéritier V, Dombret H, Thomas X.

Cancer. 2007 Dec 15;110(12):2747-55.

46.

Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis.

Millon L, Piarroux R, Deconinck E, Bulabois CE, Grenouillet F, Rohrlich P, Costa JM, Bretagne S.

J Clin Microbiol. 2005 Oct;43(10):5097-101.

47.
48.

Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation.

Larosa F, Marmier C, Robinet E, Ferrand C, Saas P, Deconinck E, Bulabois CE, Rohrlich PS, Ledu K, Helias P, Tiberghien P, Cahn JY.

Bone Marrow Transplant. 2005 May;35(9):859-68.

PMID:
15765116
49.

In vitro functional defects of bone marrow-derived CD34+ progenitors from newly diagnosed mature B-cell malignancies with bone marrow tumor involvement.

Amé-Thomas P, Deschaseaux F, Mauny F, Bulabois CE, Lamy T, Hervé P, Cahn JY, Fest T.

Exp Hematol. 2005 Mar;33(3):318-28.

PMID:
15730855
50.

Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N, Rio B, Vernant JP, Sotto JJ, Cahn JY, Blaise D, Jouet JP, Facon T, Yakoub-Agha I.

Bone Marrow Transplant. 2005 Jan;35(2):165-9.

PMID:
15531895

Supplemental Content

Loading ...
Support Center